Show simple item record

dc.contributor.authorMenghaney, Leena*
dc.date.accessioned2013-10-04T20:22:40Z
dc.date.available2013-10-04T20:22:40Z
dc.date.issued2010-04-01
dc.date.submitted2013-06-20
dc.identifier.citationPatent dispute: Delhi High Court gives a boost to access to affordable medicines., 7 (2):97-100 Indian J Med Ethicsen_GB
dc.identifier.issn0974-8466
dc.identifier.pmid20432882
dc.identifier.urihttp://hdl.handle.net/10144/302753
dc.description.abstractThe Delhi High Court has rejected the petition filed by Bayer Corporation seeking to stop the Drugs Controller of India (DCGI) from registering a generic version of a patented cancer drug. The case was filed in 2008 by Bayer to try and introduce "patent linkage" which involves linking the registration (marketing approval) of drugs with their patent status. If Bayer's plea for "patent linkage" had been accepted by the court, it would have undermined public health safeguards contained in India's patent legislation. This comment discusses the Bayer case in the context of efforts by multinational pharmaceutical companies to introduce barriers to generic competition, the only proven means of reducing the prices of medicines to make them affordable to those in need. Bayer has filed an appeal in the Supreme Court, indicating that it does not intend to give up.
dc.language.isoenen
dc.publisherForum for Medical Ethics Societyen_GB
dc.relation.urlhttp://www.ijme.in/about.htmlen_GB
dc.rightsArchived with thanks to Indian Journal of Medical Ethicsen_GB
dc.subjectHealth Policy/Access to Medicineen_GB
dc.subject.meshAntineoplastic Agentsen_GB
dc.subject.meshDrug Industryen_GB
dc.subject.meshDrug and Narcotic Controlen_GB
dc.subject.meshDrugs, Genericen_GB
dc.subject.meshGermanyen_GB
dc.subject.meshHealth Services Accessibilityen_GB
dc.subject.meshHumansen_GB
dc.subject.meshIndiaen_GB
dc.subject.meshInternational Cooperationen_GB
dc.subject.meshPatents as Topicen_GB
dc.titlePatent dispute: Delhi High Court gives a boost to access to affordable medicinesen
dc.contributor.departmentMedecins Sans Frontieres-Campaign for Access to Essential Medicines, C 236 Defence Colony, New Delhi, Indiaen_GB
dc.identifier.journalIndian Journal of Medical Ethicsen_GB
refterms.dateFOA2019-03-04T10:47:30Z
html.description.abstractThe Delhi High Court has rejected the petition filed by Bayer Corporation seeking to stop the Drugs Controller of India (DCGI) from registering a generic version of a patented cancer drug. The case was filed in 2008 by Bayer to try and introduce "patent linkage" which involves linking the registration (marketing approval) of drugs with their patent status. If Bayer's plea for "patent linkage" had been accepted by the court, it would have undermined public health safeguards contained in India's patent legislation. This comment discusses the Bayer case in the context of efforts by multinational pharmaceutical companies to introduce barriers to generic competition, the only proven means of reducing the prices of medicines to make them affordable to those in need. Bayer has filed an appeal in the Supreme Court, indicating that it does not intend to give up.


Files in this item

Thumbnail
Name:
Menghaney - Patent dispute - ...
Size:
127.6Kb
Format:
PDF
Description:
Main article

This item appears in the following Collection(s)

Show simple item record